Article
Can I legally prescribe peptides in 2026? What the FDA, your state board and USP each require
No peptide removed from the FDA's Category 2 list has been added to the 503A bulk list, so compounding the six peptides backed by the July PCAC votes still has no federal basis. Alabama's May 2026 notice bars licensees from any involvement with research-grade peptides. Ohio is enforcing through its Board of Pharmacy, and Connecticut through consumer protection law.
What three systems govern peptide prescribing?
Three systems regulate peptide therapy at once: federal drug law administered by the FDA, state licensing and practice rules administered by medical and pharmacy boards, and the compounding standards a pharmacy must meet to produce the product you order.
The FDA decides what a product is. A peptide is an approved drug, a compounded preparation made from an eligible bulk substance, or an unapproved new drug. The agency's interim 503A categories set which bulk substances a pharmacy can use, and its warning letters treat a product sold for injection as an unapproved drug even when the label says "research use only."
State boards decide what you, as a licensee, may do with it. Alabama's Board of Medical Examiners bars physicians, PAs, CRNPs, and CNMs from prescribing, administering, recommending, or supplying research-grade peptides. Ohio's Board of Pharmacy inspects clinics as terminal distributors and has summarily suspended a clinic's license for possessing research-grade product from unlicensed sources. Connecticut's Attorney General has used consumer protection law against clinics advertising compounded GLP-1s after the shortage ended. Telemedicine rules in the patient's state apply on top of all of this.
Compounding standards decide whether the product that reaches your patient was made properly. USP chapters 795 and 797 govern non-sterile and sterile compounding. A licensed 503A pharmacy filling a patient-specific prescription from an eligible bulk substance is the only route that satisfies all three systems at once.
Why does compliance in one system not cover the other two?
Clearing one hurdle does not clear the other two. Four examples:
A substance's removal from the FDA's Category 2 list, as happened to 12 peptides on April 22, 2026, does not make it eligible for compounding. None of the 12 has been added to the 503A bulk list.
A pharmacy that meets USP 797 can still be an unlawful source if the bulk substance it used is not eligible.
A valid prescription from a licensed prescriber does not help if the patient sits in a state whose board has barred the product.
A USP-compliant pharmacy does not insulate you from an informed-consent claim if the risks of the specific peptide are not documented in the chart.
A practice has to pass all three systems for every peptide, every patient, and every state it reaches.
How do the three systems interact in a multi-state practice?
State rules limit who you can prescribe to and how, and they follow the patient. Compounding rules determine what any pharmacy can lawfully make for that patient. FDA classification determines whether the product is a drug a pharmacy can touch at all. A telehealth practice with patients in six states answers to six boards, and to the pharmacy rules of whichever state the dispensing pharmacy sits in.
How does the FDA classify and regulate peptides?
Why does FDA classification matter?
The FDA does not regulate "peptides" as a category. It regulates specific molecules as drugs based on mechanism and intended use. Semaglutide, bremelanotide, BPC-157, and Melanotan II sit in very different places.
A short list of peptides are FDA-approved drugs. You can confirm each on Drugs@FDA:
- Semaglutide (Ozempic, Wegovy), a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management
- Tirzepatide (Mounjaro, Zepbound), a GIP and GLP-1 receptor agonist
- Liraglutide (Victoza, Saxenda), approved for type 2 diabetes and chronic weight management
- Tesamorelin (Egrifta), a growth hormone-releasing factor analog approved to reduce excess abdominal fat in adults with HIV and lipodystrophy
- Bremelanotide (Vyleesi), approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The FDA's approval record for Vyleesi summarizes the approval.
These products have approved manufacturers, labeled dosing, established adverse event profiles, and marketing authorization. Prescribing them follows the label and ordinary prescribing rules.
Bremelanotide is the molecule sold as "PT-141." The approved drug is Vyleesi, a single-dose autoinjector with its own label. A compounded or research-grade vial labeled "PT-141" is a different product. It has not been reviewed by the FDA, and the Vyleesi label does not vouch for its strength, purity, or sterility.
Sermorelin was approved as Geref, and the product was later discontinued. Check its current listing on Drugs@FDA, and ask your pharmacy which 503A route it relies on, before you treat sermorelin as either approved or never approved.
Which peptides can be compounded, and under what authority?
Most other peptides in clinical use have no FDA approval. BPC-157, AOD-9604, TB-500, CJC-1295, and ipamorelin are examples. Whether any of them can lawfully reach a patient depends on two provisions of the Federal Food, Drug, and Cosmetic Act: section 503A (21 U.S.C. 353a) for pharmacies compounding on patient-specific prescriptions, and section 503B (21 U.S.C. 353b) for FDA-registered outsourcing facilities.
Under 503A, a pharmacy may compound from a bulk drug substance only if that substance has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list the FDA is building. The FDA's page on bulk drug substances used in compounding states the test. While the list is being finalized, the FDA sorts nominated substances into interim categories. For Category 1, the FDA does not intend to take action against compounding while it reviews the nomination. Category 2 substances may not be compounded. A substance in neither category, including the 12 peptides removed from Category 2 on April 22, 2026, has no federal basis for compounding.
Under 503B, an outsourcing facility works from a different list. It may compound from a bulk substance only if the FDA has found a clinical need for it or the finished drug is on the FDA shortage list. The FDA explains the rule on its page on bulk drug substances under section 503B and publishes the 503B bulks list itself. The 503A and 503B lists are developed separately, and a substance can sit on one and not the other.
Every peptide has one of three statuses: approved, compoundable under a specific statutory pathway, or an unapproved new drug.
What does informed consent need to say?
For an FDA-approved peptide, consent covers the established risks and benefits on the label. For a compounded peptide, consent should also state that the product is not FDA-approved, has not been reviewed for safety or efficacy, and carries risks that are not fully characterized. Consent has a limit. Alabama's notice says a consent form cannot be used to waive the provider's duty of care.
What can a 503A or 503B pharmacy do?
A 503A pharmacy compounds for an identified patient on a valid prescription, keeps patient-specific records, does not compound in anticipation of orders beyond the limited history the statute allows, and must comply with the USP chapters on pharmacy compounding. Its bulk substance must meet the 503A eligibility test above and come from an FDA-registered facility. Most clinic suppliers are 503A.
A 503B outsourcing facility registers with the FDA, compounds without patient-specific prescriptions, and may ship to multiple practices. It must follow current good manufacturing practice (CGMP); USP 797 does not apply. Its bulk substance must be on the 503B bulks list or the finished drug must be in shortage. If your peptide comes from a 503B facility, confirm its registration on the FDA's list of registered outsourcing facilities and ask for its most recent inspection outcome. The FDA posts warning letters and Form 483 observations for registered facilities.
Which USP compounding standards apply?
USP General Chapter 795 covers non-sterile compounding. USP General Chapter 797 covers sterile compounding, which includes every injectable peptide. The revised 797 took effect November 1, 2023. USP 825 is the chapter for radiopharmaceuticals and does not apply to peptide compounding.
For an injectable peptide, these are the 797 points that matter to a prescriber.
Sterile compounding takes place inside an ISO Class 5 primary engineering control (a hood or isolator) within a classified or segregated compounding area, with documented environmental monitoring.
Compounders must complete documented training and competency assessment, including gloved fingertip and media-fill testing, on a recurring schedule, with a designated person responsible for oversight.
Bulk substances used in sterile compounding must meet the standards of an applicable USP or NF monograph where one exists and come from an FDA-registered facility, with a certificate of analysis on file.
Each compounded sterile preparation is assigned a beyond-use date based on its 797 category, storage conditions, and sterility testing. Ask the pharmacy which category your preparation falls in and how the date on the label was derived.
The preparation must be free of microbial contamination and within endotoxin limits, and the pharmacy must be able to show how potency was verified for the batch.
Each vial carries the patient name, drug name, strength, beyond-use date, and compounding record identifiers that trace back to the lot of bulk substance used.
What are Alabama, Connecticut, California, and Ohio doing?
Peptide rules are set state by state. Here is what is on the public record in four states. Check your own state's medical and pharmacy boards for anything newer.
What did Alabama's May 2026 notice actually prohibit?
The Alabama Board of Medical Examiners' May 2026 notice is a prohibition. It does not set documentation standards for peptide prescribing. Under the notice, a physician may not compound, administer, or dispense a non-FDA-approved or research-grade peptide to a patient, may not delegate that to a CNM, CRNP, or PA, and may not advise, recommend, supply, or prescribe one. CNMs, CRNPs, and PAs have no independent authority to do so because no such peptide appears on any approved formulary. A consent form describing the product as "research-grade" does not reduce the provider's liability, and a patient cannot waive the provider's duty of care.
The notice also states the sourcing rule that applies to every prescription product in Alabama: it must come from an entity permitted by the Alabama State Board of Pharmacy and be prescription quality. That rule is where compounded peptides sit. A compounded peptide from a permitted pharmacy using a 503A-eligible bulk substance is not what the notice prohibits. A research-grade vial is.
The notice applies to physicians, PAs, CRNPs, and CNMs.
What should you document for any compounded peptide?
The Board has not published a charting standard for lawful compounded peptides. The list below is Scriptura's recommendation, not a Board requirement.
- Written informed consent for each peptide, stating that the product is compounded, is not FDA-approved, and carries risks that are not fully characterized. A blanket "peptide therapy" form does not do this.
- A baseline assessment with the biomarkers relevant to the peptide's proposed effect, recorded before the first dose.
- Follow-up labs on a schedule you define for the peptide, with your interpretation written in the chart alongside the result.
- A charted link between the clinical indication and the decision to prescribe, so a reviewer can see why this patient received this peptide.
- A record of who prescribed, when, and from which pharmacy, with the pharmacy's permit number and the certificate of analysis for the batch on file.
If your practice uses telemedicine for peptide patients, confirm the telehealth rules in the patient's state on prescribing without a prior in-person visit. Alabama's notice says nothing about telemedicine, and the requirement varies by state.
How is Connecticut enforcing?
Connecticut's actions have come from the Attorney General under the Connecticut Unfair Trade Practices Act. The state has no peptide-specific health department rule that we found, and the record so far concerns GLP-1 drugs.
On May 21, 2025, the Attorney General's office wrote to weight-loss clinics and med spas warning that marketing compounded GLP-1 drugs may violate the Act. On December 3, 2025, it announced cease and desist letters to spas in Avon, Brookfield, and Danbury that kept advertising compounded semaglutide or tirzepatide. The same release reports a settlement requiring an online seller, Triggered Brand, to stop selling unapproved GLP-1 drugs, and an ongoing investigation into a trade platform that had facilitated sales of "research grade" GLP-1s to U.S. consumers.
What does California require of out-of-state compounders?
A nonresident pharmacy may not compound sterile drug products for shipment into California without a California sterile compounding license, which the Board of Pharmacy issues only after inspecting the location (Business and Professions Code section 4127.2). If your injectable peptides ship to California patients from an out-of-state 503A pharmacy, confirm that license. For peptide-specific actions, check the Medical Board of California and the California State Board of Pharmacy directly.
What is Ohio's Board of Pharmacy enforcing?
Ohio's action came from the Board of Pharmacy, which licenses clinics as terminal distributors of dangerous drugs. In February 2026, it issued a summary suspension of a clinic's terminal distributor license over research-grade product bought from unlicensed sources. A summary suspension takes effect before a hearing.
How do you vet a compounding pharmacy?
Choosing a compounding pharmacy is a clinical and legal decision. The pharmacy you select, and how you keep checking it, determines whether the product is lawful and whether it is what the label says.
What should a compounding pharmacy show you?
- A current state license that covers compounding, and a nonresident license in each state it ships to
- A licensed pharmacist-in-charge who is available for consultation
- Documents showing current certification of its ISO Class 5 primary engineering controls
- A certificate of analysis for each peptide batch, with third-party lab verification
- Traceability of each bulk substance to its manufacturer, with proof the manufacturer is FDA-registered
- A written quality control procedure
- Beyond-use dating and storage stability documentation
- Patient labeling with lot numbers, beyond-use dates, and storage instructions
- Proof of liability insurance
- Cooperation with your audit and record-keeping requests
A pharmacy that cannot show all of these is a compliance risk.
What should you require from your compounding pharmacy?
Ask for a certificate of analysis (CoA) for every batch you dispense, signed by a licensed pharmacist and verified by a third-party lab. The CoA should specify:
- Peptide identity (HPLC or mass spectrometry confirmation)
- Concentration, with the acceptance range the pharmacy applied
- Sterility results
- Endotoxin content, for injectables
- Beyond-use date and storage conditions
Ask for sourcing documentation. The pharmacy should show that each bulk substance meets the 503A eligibility test (a USP or NF monograph, a component of an FDA-approved drug, or the 503A bulks list), was made by an FDA-registered facility, and came with a certificate of analysis. A research chemical catalog does not meet that standard, whatever its brand.
Ask for the pharmacy's written procedure for testing, validating, and releasing each batch.
Review the patient label before the pharmacy uses it. It should include:
- Patient name
- Peptide name and concentration
- Lot number
- Compounding date and beyond-use date
- Storage instructions (for example, "Refrigerate at 2 to 8°C")
- A contact for reporting adverse events (your clinic or the pharmacy)
How does a complaint reach a state board?
Each board sets its own process, and we make no claim that boards work the same way. These are common ways a peptide practice comes to a board's attention.
A patient complaint. A patient has an adverse event or is unhappy with care and files a complaint. The board then reviews whether your documentation supports your clinical decisions.
A pharmacy or pharmacy board action. Ohio's order shows the pharmacy board inspecting a clinic directly. Action against a compounding pharmacy can also lead a regulator to the prescribers it supplied.
A report from another licensee or a member of the public. Boards accept complaints from anyone.
Your state medical board's website explains how it receives and handles complaints. The Federation of State Medical Boards links to every state board.
What does an audit-ready peptide practice need?
An audit-ready clinic documents every prescribing decision and every compounding order well enough to defend it. The test is whether you could defend the record to a state medical board or in court.
The lab panels and follow-up schedules in this section are Scriptura's suggested monitoring, not a label or guideline requirement. Where an FDA label exists, follow the label. Adjust the rest to the patient and your own clinical judgment.
What should the intake record?
The intake should record:
- Chief complaint and reason for seeking peptide therapy
- Pertinent medical history (cardiovascular, renal, hepatic, endocrine, psychiatric)
- Current medications, to identify interactions
- Allergies and adverse event history
- Contraindication screening for the specific peptide
- Baseline physical exam (vitals and the relevant organ-system exam)
- Baseline labs specific to the peptide
An intake form with checkboxes and space for narrative works. An EHR with required fields works better. Complete the intake before starting peptide therapy, and update it when clinical status changes.
Which baseline labs should you order?
Order baseline labs before the first dose. Which labs depend on the peptide. The panels below are suggestions, as noted above.
Growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin):
- Comprehensive metabolic panel (CMP)
- Complete blood count (CBC)
- Fasting glucose or HbA1c
- IGF-1
Bremelanotide (Vyleesi, or compounded "PT-141"):
- Blood pressure. The Vyleesi label contraindicates the drug in patients with uncontrolled hypertension or known cardiovascular disease, and warns of transient increases in blood pressure and decreases in heart rate after each dose. It directs prescribers to consider the patient's cardiovascular risk and confirm that blood pressure is well controlled before starting and periodically during treatment.
- The label describes the approved product only. A compounded preparation has no label of its own.
BPC-157 and TB-500 have no FDA label and no federal basis for compounding as of this writing, so no label or guideline defines a baseline panel for them. Where a prescriber is managing a patient already exposed to one, a CMP, CBC, and inflammatory markers (hsCRP, ESR) are a reasonable starting record.
Write your interpretation in the chart: why you ordered each lab, what it shows, and how it informs the prescribing decision.
What should every peptide prescribing record show?
We recommend that each prescription record show eight things.
- The specific clinical indication. "GI dysfunction with malabsorption" is an indication. "Wellness optimization" is not.
- The evidence you reviewed for the peptide in that indication, such as peer-reviewed studies or professional society guidance.
- Written informed consent covering the product's FDA status, known and unknown risks, the lack of long-term safety data, the monitoring plan, and alternative therapies.
- The baseline assessment: intake, physical exam, and baseline labs.
- The prescribing decision: dose, frequency, duration, and the compounding pharmacy selected.
- Patient education: how to administer and store the product, which side effects to report, and when to contact you.
- The monitoring plan and the follow-up visits and labs that actually took place.
- Any adverse events, your clinical response, and whether you continued, modified, or stopped the peptide.
A template or an EHR-embedded workflow keeps this manageable, and the record holds up in a medical board review or a malpractice deposition.
How should you document informed consent?
Have the consent conversation, then document it in writing. At minimum:
"[Patient name], I am prescribing [peptide name] for [indication]. You should know:
- This peptide is not FDA-approved.
- It is compounded by [pharmacy name] under USP 797 standards, but the FDA has not reviewed its safety or efficacy.
- Known risks include [list specific risks documented in the literature].
- Unknown risks are possible because long-term safety data are limited.
- You will need baseline and ongoing labs to monitor for adverse effects.
- You can stop the peptide at any time.
- Alternatives to peptide therapy include [list].
I have reviewed these points with you, answered your questions, and you have agreed to proceed."
Have the patient sign and date it. Keep the signed copy in the chart.
How should you schedule follow-up labs?
Define your monitoring schedule for each peptide and document it. The example below is Scriptura's suggestion, not a label or guideline requirement.
Growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin):
- Baseline: CMP, CBC, fasting glucose or HbA1c, IGF-1
- An early clinical check for symptoms and adverse effects
- Repeat IGF-1 and fasting glucose after the dose has had time to take effect
- A repeat of the baseline panel at intervals you set if therapy continues
Record the visits and labs that actually happen. If a patient is lost to follow-up, document your attempts to reach them and your reasoning for continuing or stopping the peptide.
How should you organize the patient record?
Follow your state's medical-record retention rule. Organize the record by patient:
- Intake form and informed consent
- Baseline and follow-up labs, with your interpretation
- Prescribing decisions and peptide orders
- Patient education materials and instructions
- Adverse events or complications
- Phone notes and emails about side effects or monitoring results
Digital records with timestamps are best. If you use paper, keep entries legible and date every one.
What pharmacy records should you keep?
Keep a record for each peptide prescription:
- Pharmacy name, location, license number, and pharmacist-in-charge
- Peptide name, concentration, quantity, and beyond-use date
- Certificate of analysis for the batch given to the patient
- Date dispensed and date given to the patient
- Any adverse reports or quality concerns
If a patient reports a problem with the peptide, such as an injection-site infection or an unexpected side effect, document your investigation. Record whether you contacted the pharmacy, whether the batch was retested, and whether the patient stored and handled the product correctly.
What did the July 2026 PCAC vote change for compounding today?
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to consider whether seven peptides should be added to the 503A bulks list, the list of substances a state-licensed pharmacy may use to compound a patient-specific prescription. The seven were BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. All seven had been removed from the FDA's Category 2 list on April 22, 2026, after their nominations were withdrawn. Each was evaluated for a specific proposed use, in both free-base and acetate forms.
The committee was not asked whether any of these should be approved as drugs. No peptide on the agenda has a new drug application, and PCAC has no role in approval. The question was narrower: is there enough physical and chemical characterization, safety data, evidence of effectiveness, and history of compounding use to let pharmacies compound it.
FDA review staff recommended against all seven. The committee disagreed on six. The vote counts below are as reported by McDermott Will & Emery and RAPS; FDA minutes are pending.
July 23: BPC-157, evaluated for ulcerative colitis, recommended 8 to 6 with one abstention. KPV, for inflammatory conditions and wound healing, 8 to 6 with one abstention. TB-500, for wound healing, 8 to 6 with one abstention. MOTS-c, for osteoporosis and obesity, 7 to 5 with two abstentions.
July 24: Emideltide, for insomnia, narcolepsy, and opioid withdrawal, rejected 6 to 7 with one abstention. Epitalon, for insomnia, recommended 7 to 4 with one abstention according to McDermott; RAPS reported 7 to 5. Semax, for migraine, cerebral ischemia, and trigeminal neuralgia, recommended 8 to 5 with one abstention.
The votes changed nothing today. PCAC is advisory. A substance reaches the 503A bulk list only through FDA rulemaking, which means a proposed rule, a comment period, and a final rule in the Federal Register. As of October 19, 2026, we have found no proposed rule for any of the six, so compounding any of them still has no federal basis, and a pharmacy that does so is working outside Section 503A. The remaining five peptides removed from Category 2 in April (GHK-Cu, LL-37, Dihexa, Melanotan II, and PEG-MGF) are scheduled for PCAC review before the end of February 2027.
One caution for prescribers. The committee's margins were one or two votes in most cases, over the written objection of agency scientists. A recommendation is not a rule, and describing any of these peptides to patients as FDA-recommended or FDA-approved would misstate what happened.
What is already on record, and what should you watch?
No regulator has published a forecast of which states act next or when. This is what is documented:
- Alabama's Board of Medical Examiners barred licensee involvement with research-grade peptides in its May 2026 notice
- Connecticut's Attorney General has acted against med spas and online sellers of GLP-1 drugs under consumer protection law (December 2025 release)
- Ohio's Board of Pharmacy has summarily suspended a clinic's terminal distributor license over research-grade product (order)
- PCAC recommended six peptides in July 2026, and no rule has appeared in the Federal Register
Watch your own state medical board and pharmacy board notices, and the Federal Register for a proposed 503A bulk rule.
Frequently asked questions
Can I prescribe peptides without informed consent?
No. Written, peptide-specific consent is expected for any compounded peptide, and it should state that the product is not FDA-approved. Consent also has a limit: the Alabama Board's notice says a consent form does not reduce the provider's liability and cannot waive the duty of care.
What is the difference between research-use-only and compounded peptides?
Research-use-only peptides are sold for laboratory research, not human administration, and their purity and contents are not verified to any drug standard. Compounded peptides are prepared by a licensed pharmacy from an eligible bulk substance, under USP 797 for sterile injectables. Do not prescribe, administer, or recommend a peptide labeled "research use only." Alabama's notice bars it outright, and the FDA treats such products as unapproved new drugs when they are sold for human use.
Is a patient waiver enough to protect me if something goes wrong?
No. A waiver does not shield you from liability or board discipline. Alabama's notice says a patient cannot waive the provider's duty of care. You still have to prescribe appropriately, document carefully, and monitor.
What if my state has no peptide rule but the FDA restricts the substance?
Federal law applies in every state. If a bulk substance is in Category 2, or is in no category and not otherwise 503A-eligible, a pharmacy has no federal basis to compound it, whatever your state board has or has not said. Check the FDA's current position and talk to your attorney before you prescribe.
How often should I check my compounding pharmacy's compliance status?
We suggest at least once a year, and again whenever something changes. Check the FDA's warning letters, look up the pharmacy's license with its state board, and ask for current certificates of analysis. If the pharmacy receives a warning letter or loses its license, stop ordering and review which patients received its product.
Do I need a separate informed consent for each peptide?
Yes. A blanket consent for "peptide therapy" does not cover the specific risks, unknowns, and indication of each peptide. Document consent for each one you prescribe.
What should I do if a state board investigates me?
Contact your malpractice carrier and an attorney experienced in healthcare regulatory defense right away. Preserve all records. Respond to the board through your attorney.
How do I know which peptides I can prescribe in my state?
Start with two tests. A research-grade product should not be prescribed at all. A compounded peptide should be prescribed only when its bulk substance is 503A-eligible, and the pharmacy is licensed in the patient's state. Then check your state medical board and pharmacy board for notices that go further, and ask the board directly if you are unsure.
What are the consequences of non-compliance?
It depends on the board and the facts. Boards can reprimand, restrict, suspend, or revoke a license, and Ohio's order shows a summary suspension taking effect before a hearing. Civil liability to a harmed patient is separate, and distributing unapproved drugs can bring federal charges.
About the author
How can Scriptura help multi-state prescribers?
If you prescribe peptides across state lines, book a demo to see how Scriptura's clinical decision support works for prescribers. Clinicians verify their license before platform access.
Educational and regulatory information only
This article is for educational and regulatory information only. It is not legal or medical advice and does not create an attorney-client or clinician-patient relationship. Rules change. Confirm current requirements with your state boards and a healthcare attorney licensed in your state before acting.
